Eva Rakasz
Overview
Explore the profile of Eva Rakasz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lim S, Lee J, Osuna C, Vikhe P, Schalk D, Chen E, et al.
Science
. 2024 Feb;
383(6687):1104-1111.
PMID: 38422185
The eradication of the viral reservoir represents the major obstacle to the development of a clinical cure for established HIV-1 infection. Here, we demonstrate that the administration of N-803 (brand...
2.
Hangartner L, Beauparlant D, Rakasz E, Nedellec R, Hoze N, McKenney K, et al.
Sci Transl Med
. 2021 Mar;
13(585).
PMID: 33731434
Protection from immunodeficiency virus challenge in nonhuman primates (NHPs) by a first-generation HIV broadly neutralizing antibody (bnAb) b12 has previously been shown to benefit from interaction between the bnAb and...
3.
Toledo N, Li H, Omange R, Dacoba T, Crecente-Campo J, Schalk D, et al.
Front Immunol
. 2020 Sep;
11:1935.
PMID: 32983121
Studies have shown that vaccine vectors and route of immunization can differentially activate different arms of the immune system. However, the effects of different HIV vaccine immunogens on mucosal inflammation...
4.
Moreno G, Newman C, Koenig M, Mohns M, Weiler A, Rybarczyk S, et al.
J Virol
. 2019 Dec;
94(5).
PMID: 31801867
By the end of the 2016 Zika virus (ZIKV) outbreak, it is estimated that there were up to 100 million infections in the Americas. In approximately one in seven infants...
5.
Li H, Hai Y, Lim S, Toledo N, Crecente-Campo J, Schalk D, et al.
PLoS One
. 2018 Aug;
13(8):e0202997.
PMID: 30153293
HIV mutates rapidly and infects CD4+ T cells, especially when they are activated. A vaccine targeting conserved, essential viral elements while limiting CD4+ T cell activation could be effective. Learning...
6.
Ellis-Connell A, Balgeman A, Zarbock K, Barry G, Weiler A, Egan J, et al.
J Virol
. 2017 Nov;
92(3).
PMID: 29118125
Developing biological interventions to control human immunodeficiency virus (HIV) replication in the absence of antiretroviral therapy (ART) could contribute to the development of a functional cure. As a potential alternative...
7.
Martins M, Shin Y, Gonzalez-Nieto L, Domingues A, Gutman M, Maxwell H, et al.
PLoS Pathog
. 2017 Jul;
13(7):e1006529.
PMID: 28732035
The ability to control lentivirus replication may be determined, in part, by the extent to which individual viral proteins are targeted by the immune system. Consequently, defining the antigens that...
8.
Martins M, Tully D, Shin Y, Gonzalez-Nieto L, Weisgrau K, Bean D, et al.
AIDS Res Hum Retroviruses
. 2017 May;
33(8):843-858.
PMID: 28503929
Effector memory T cell (T) responses display potent antiviral properties and have been linked to stringent control of simian immunodeficiency virus (SIV) replication. Since recurrent antigen stimulation drives the differentiation...
9.
Haase A, Rakasz E, Schultz-Darken N, Nephew K, Weisgrau K, Reilly C, et al.
PLoS One
. 2015 Jun;
10(6):e0129465.
PMID: 26057743
Measures to prevent sexual mucosal transmission are critically needed, particularly to prevent transmission to young women at high risk in the microepidemics in South Africa that disproportionally contribute to the...
10.
Mendoza D, Migueles S, Rood J, Peterson B, Johnson S, Doria-Rose N, et al.
PLoS Pathog
. 2013 Mar;
9(2):e1003195.
PMID: 23468632
Although the study of non-human primates has resulted in important advances for understanding HIV-specific immunity, a clear correlate of immune control over simian immunodeficiency virus (SIV) replication has not been...